Agenus (AGEN) +7.3% premarket after announcing efficacy shown with GlaxoSmithKline's (GSK) Phase...

|About: Agenus (AGEN)|By:, SA News Editor

Agenus (AGEN) +7.3% premarket after announcing efficacy shown with GlaxoSmithKline's (GSK) Phase 3 malaria vaccine candidate, which contains AGEN's Qs-21 Stimulon adjuvant. Infants at the trial receiving the vaccine experienced one-third fewer episodes of both clinical and severe malaria.